New technologies like generative artificial intelligence (Gen AI) and digital-twins could potentially rewire the life sciences sector, with several promising use cases across the molecule-to-market continuum.
McKinsey Exec On Generative AI in R&D And Pharmacovigilance, Digital Twins
McKinsey & Company's senior partner Vikas Bhadoria, in this first instalment of a wide-ranging two-part interview with Scrip, outlines a number of use cases to define where pharma currently is and the potential value that can be unlocked as industry adopts new technologies such as generative AI, digital twins and the metaverse.
More from Business
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.